2017
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Hechtman J, Benayed R, Hyman D, Drilon A, Zehir A, Frosina D, Arcila M, Dogan S, Klimstra D, Ladanyi M, Jungbluth A. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. The American Journal Of Surgical Pathology 2017, 41: 1547-1551. PMID: 28719467, PMCID: PMC5636652, DOI: 10.1097/pas.0000000000000911.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsyDNA Copy Number VariationsFemaleGene DosageGene FusionGene RearrangementGenetic Predisposition to DiseaseHumansImmunohistochemistryMaleMembrane GlycoproteinsMutationNeoplasmsPhenotypePredictive Value of TestsProspective StudiesReceptor, trkAReceptor, trkBReceptor, trkCReceptors, Nerve Growth FactorReproducibility of ResultsSequence Analysis, DNAConceptsNeurotrophic tyrosine receptor kinasePan-TRK immunohistochemistryNTRK fusionsETV6-NTRK3 fusionNTRK rearrangementsMembrane accentuationETV6-NTRK3Fusion transcriptsDNA-based next-generation sequencing assaysMismatch repair-deficient colorectal carcinomasCase of secretory carcinomaDetection of NTRK fusionsDetect NTRK fusionsNext-generation sequencing assayLMNA-NTRK1 fusionTyrosine receptor kinaseFunctional fusion transcriptsPositive IHC casesPan-TrkIHC casesSecretory carcinomaAdvanced malignanciesCongenital fibrosarcomaMSK-IMPACTLMNA-NTRK1
2016
Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6–NTRK3 fusion
Dogan S, Wang L, Ptashkin R, Dawson R, Shah J, Sherman E, Tuttle R, Fagin J, Klimstra D, Katabi N, Ghossein R. Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6–NTRK3 fusion. Modern Pathology 2016, 29: 985-995. PMID: 27282352, PMCID: PMC5019170, DOI: 10.1038/modpathol.2016.115.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorDisease ProgressionDisease-Free SurvivalFemaleGene FusionGene RearrangementGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaleMammary Analogue Secretory CarcinomaMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingOncogene Proteins, FusionPhenotypeThyroid NeoplasmsTreatment OutcomeConceptsMammary analog secretory carcinomaFree of diseaseETV6-NTRK3 fusionPapillary thyroid carcinomaS-100 proteinFluorescence in situ hybridizationSecretory carcinomaETV6 rearrangementThyroid carcinomaGCDFP-15TTF-1Minority of papillary thyroid carcinomasWell-differentiated papillary thyroid carcinomaThyroid glandS-100Papillary thyroid carcinoma componentAssociated with long-term survivalETV6-NTRK3 gene fusionSalivary glandsThyroid carcinoma componentFollicular cell originLow-grade tumorsHigher T stageLocally aggressive tumorSalivary gland counterparts
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply